Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. News
  7. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wells Fargo Adjusts Pfizer Price Target to $65 From $60, Maintains Overweight Rating

01/07/2022 | 01:27pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about PFIZER, INC.
11:52aGLOBAL MARKETS LIVE : Pfizer, Tesla, Holcim, Novartis, Ford...
10:39aWALL STREET STOCK EXCHANGE : China added to the list of investors' fears
08:08aPfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European C..
AQ
07:11aINSIDER SELL : Pfizer
MT
05/15Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU
MT
05/13Pfizer Files Lawsuit In Australia To Halt Sales Of BRENZYS (Etanercept)
AQ
05/13N.Korea gets offers of aid to fight COVID as it lacks vaccines
RE
05/12PFIZER, INC. : Ex-dividend day for
FA
05/11PFIZER INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 223 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,47x
Yield 2022 3,20%
Capitalization 284 B 284 B -
EV / Sales 2022 2,63x
EV / Sales 2023 3,45x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 50,67 $
Average target price 57,79 $
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-14.19%280 096
JOHNSON & JOHNSON3.38%465 363
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421
NOVO NORDISK A/S1.92%238 221